APRE Relative Valuation
APRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APRE is overvalued; if below, it's undervalued.
Historical Valuation
Aprea Therapeutics Inc (APRE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -1.40. The fair price of Aprea Therapeutics Inc (APRE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.03 USD , Aprea Therapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：1.03
Fair
Undervalued
-0.70
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Aprea Therapeutics Inc. (APRE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.27. The thresholds are as follows: Strongly Undervalued below -0.60, Undervalued between -0.60 and -0.16, Fairly Valued between 0.71 and -0.16, Overvalued between 0.71 and 1.14, and Strongly Overvalued above 1.14. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.38
EV/EBIT
Aprea Therapeutics Inc. (APRE) has a current EV/EBIT of 0.38. The 5-year average EV/EBIT is 0.25. The thresholds are as follows: Strongly Undervalued below -1.00, Undervalued between -1.00 and -0.38, Fairly Valued between 0.87 and -0.38, Overvalued between 0.87 and 1.49, and Strongly Overvalued above 1.49. The current Forward EV/EBIT of 0.38 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Aprea Therapeutics Inc. (APRE) has a current PS of 0.00. The 5-year average PS is 55.92. The thresholds are as follows: Strongly Undervalued below -82.59, Undervalued between -82.59 and -13.33, Fairly Valued between 125.18 and -13.33, Overvalued between 125.18 and 194.44, and Strongly Overvalued above 194.44. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Aprea Therapeutics Inc. (APRE) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.07. The thresholds are as follows: Strongly Undervalued below -0.37, Undervalued between -0.37 and -0.22, Fairly Valued between 0.08 and -0.22, Overvalued between 0.08 and 0.23, and Strongly Overvalued above 0.23. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Aprea Therapeutics Inc. (APRE) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.33. The thresholds are as follows: Strongly Undervalued below -1.15, Undervalued between -1.15 and -0.74, Fairly Valued between 0.08 and -0.74, Overvalued between 0.08 and 0.48, and Strongly Overvalued above 0.48. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Aprea Therapeutics Inc (APRE) has a current Price-to-Book (P/B) ratio of 0.64. Compared to its 3-year average P/B ratio of 0.80 , the current P/B ratio is approximately -19.52% higher. Relative to its 5-year average P/B ratio of 0.68, the current P/B ratio is about -5.98% higher. Aprea Therapeutics Inc (APRE) has a Forward Free Cash Flow (FCF) yield of approximately -182.08%. Compared to its 3-year average FCF yield of -103.26%, the current FCF yield is approximately 76.33% lower. Relative to its 5-year average FCF yield of -114.85% , the current FCF yield is about 58.54% lower.
0.64
P/B
Median3y
0.80
Median5y
0.68
-182.08
FCF Yield
Median3y
-103.26
Median5y
-114.85
Competitors Valuation Multiple
The average P/S ratio for APRE's competitors is 0.82, providing a benchmark for relative valuation. Aprea Therapeutics Inc Corp (APRE) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -99.48%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of APRE decreased by 67.78% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.07K to -160.84K.
The secondary factor is the Revenue Growth, contributed -99.48%to the performance.
Overall, the performance of APRE in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Aprea Therapeutics Inc (APRE) currently overvalued or undervalued?
What is Aprea Therapeutics Inc (APRE) fair value?
How does APRE's valuation metrics compare to the industry average?
What is the current P/B ratio for Aprea Therapeutics Inc (APRE) as of Dec 05 2025?
What is the current FCF Yield for Aprea Therapeutics Inc (APRE) as of Dec 05 2025?
What is the current Forward P/E ratio for Aprea Therapeutics Inc (APRE) as of Dec 05 2025?